[AMRN]
Mid
Mid
2026-08-31 01:44:25
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits
Mid
2026-07-30 07:17:24
Amarin expects positive full-year 2026 cash flow as VASCEPA market share reaches 48% and Europe demand rises 69%